Appendix

Section 1. Supplementary Figures and Tables

Table A1.1. Percent of COVID-19 deaths after January 15, 2021 averted. Values are medians and 95% confidence intervals based on 200 pairs of stochastic simulations. Deaths averted are computed by comparing a simulation of the specified vaccine strategy to a simulation without vaccination.

Vaccine rollout date			January 15		February 15		
Vacci	ne adherence	0.5	0.7	0.9	0.5	0.7	0.9
	All	48 (43-53)	48 (42-54)	48 (43-53)	30 (25-36)	30 (25-35)	31 (24 - 36)
Infection	>65	49 (44-54)	50 (45-55)	51 (45-55)	32 (24-37)	33 (27-38)	33 (27-39)
blocking	high risk adults	52 (46-56)	54 (48-58)	54 (50-59)	34 (27-39)	35 (30-40)	36 (30-41)
2 dose	>65 + high risk	51 (46-56)	52 (48-58)	53 (48-58)	33 (29-39)	34 (27-40)	36 (29-40)
	10 phase	52 (47-56)	54 (49-58)	56 (51-60)	34 (28-40)	36 (30-42)	38 (32-43)
	No priorities	32 (25-37)	32 (27-38)	33 (26-38)	20 (13-26)	19 (13-25)	19 (12-25)
Symptom	>65	36 (30-42)	40 (34-44)	42 (38-46)	23 (18-29)	26 (19-32)	28 (20-33)
blocking	high risk adults	38 (32-43)	41 (35-47)	44 (39-49)	25 (18-30)	27 (21-33)	29 (24-34)
2 dose	>65 + high risk	38 (32-43)	43 (38-49)	45 (41-50)	25 (19-30)	28 (22-33)	30 (24-35)
	10 phase	40 (35-45)	46 (40-51)	51 (45-56)	27 (21-33)	32 (25-37)	34 (29-39)
	No priorities	47 (41-51)	46 (41-51)	47 (41-52)	30 (22-35)	29 (23-35)	29 (22-35)
II. J. 24	>65	47 (43-53)	48 (43-54)	50 (43-55)	31 (25-36)	32 (25-37)	33 (27-38)
Hybrid 2 dose	high risk adults	50(43-55)	52(46-57)	53(47-58)	33(27-38)	34(27-39)	35(29-40)
	>65 + high risk	50 (45-54)	51 (46-56)	53 (46-57)	32 (25-37)	34 (27-39)	34 (28-40)
	10 phase	50 (45-55)	53 (48-58)	56 (51-60)	34 (28-39)	36 (30-41)	37 (31-44)
	No priorities	65 (61-68)	65 (62-69)	65 (63-69)	44 (39-49)	44 (40-49)	44 (40-50)
Infection	>65	66 (62-69)	66 (63-70)	68 (63-71)	45 (41-50)	47 (42-52)	47 (43-52)
blocking	high risk adults	66 (62-69)	68 (64-72)	70 (66-73)	46 (41-52)	48 (43-53)	49 (43-54)
1 dose	>65 + high risk	66 (63-70)	68 (64-71)	69 (65-73)	46 (41-51)	48 (43-53)	49 (44-54)
	10 phase	66 (63-70)	69 (66-73)	71 (67-74)	47 (41-51)	49 (44-54)	51 (46-55)
	No priorities	46 (39-50)	50 (45-55)	51 (47-56)	31 (25-36)	33 (27-39)	34 (28-38)
Symptom	>65	48 (42-52)	54 (49-58)	57 (52-61)	33 (28-38)	37 (32-43)	39 (33-45)
blocking	high risk adults	49 (43-53)	55 (49-60)	58 (54-63)	34 (29-39)	38 (33-43)	41 (35-45)
I dose	>65 + high risk	49 (43-53)	55 (51-60)	60 (55-64)	34 (28-39)	39 (33-43)	42 (36-46)
	10 phase	50 (45-54)	57 (53-62)	63 (58-67)	35 (29-40)	41 (36-46)	45 (39-50)
	No priorities	63 (59-67)	64 (60-68)	64 (59-67)	43 (37-47)	43 (37-48)	44 (38-48)
Hybrid	>65	64 (59-68)	65 (61-69)	66 (62-70)	44 (39-49)	45 (40-50)	46 (41-52)
1 dose	high risk adults	65 (61-68)	67 (62-70)	68 (65-72)	45 (39-49)	47 (41-52)	48 (43-52)
	>65 + high risk	64 (60-68)	67 (63-70)	68 (64-71)	45 (40-50)	47 (42-51)	48 (44-52)
	10 phase	65 (61-69)	68 (64-72)	70 (66-73)	46 (40-50)	48 (44-53)	50 (46-54)

Vaccine rollout date			January 15		February 15			
Vac	ccine adherence	0.5	0.7	0.9	0.5	0.7	0.9	
N	o vaccination		19 (17-24)					
	All	17 (14-20)	17 (14-19)	17 (15-19)	18 (16-21)	18 (16-21)	18 (16-20)	
Infection	>65	17 (14-20)	17 (14-19)	17 (13-19)	18 (16-20)	18 (16-20)	18 (15-20)	
blocking	high risk adults	17 (14-19)	16 (13-20)	16 (13-19)	18 (16-20)	18 (16-20)	18 (16-20)	
2 dose	>65 + high risk	17 (14-19)	16 (14-19)	16 (13-19)	18 (16-20)	18 (16-20)	18 (16-20)	
	10 phase	16 (13-19)	16 (13-19)	16 (12-19)	18 (16-20)	18 (15-20)	18 (15-20)	
	No priorities	18 (15-20)	18 (15-20)	18 (15-20)	19 (16-21)	18 (16-21)	19 (16-22)	
Symptom	>65	18 (15-20)	18 (14-21)	17 (14-20)	18 (16-21)	18 (16-20)	18 (16-20)	
blocking	high risk adults	18 (15-20)	17 (14-19)	17 (14-20)	18 (16-21)	18 (16-20)	18 (16-20)	
2 dose	>65 + high risk	18 (14-20)	17 (14-20)	17 (14-19)	18 (16-21)	18 (16-20)	18 (16-20)	
	10 phase	17 (14-20)	17 (13-19)	16 (13-19)	18 (15-20)	18 (16-20)	18 (16-20)	
	No priorities	18 (15-20)	17 (14-20)	17 (14-20)	19 (16-21)	18 (16-21)	18 (16-21)	
	>65	17 (14-19)	17 (14-19)	17 (14-19)	18 (16-20)	18 (16-20)	18 (16-20)	
Hybrid 2 dose	high risk adults	17 (14-19)	16 (14-19)	16 (13-19)	18 (16-20)	18 (16-20)	18 (16-20)	
- uose	>65 + high risk	17 (14-19)	16 (14-19)	16.5 (14-19)	18 (16-20)	18 (16-20)	18 (16-20)	
	10 phase	17 (13-20)	17 (14-19)	16 (13-19)	18 (16-20)	18 (16-20)	18 (15-20)	
	No priorities	15 (13-17)	15 (12-17)	15 (12-18)	18 (15-20)	18 (15-20)	18 (16-20)	
Infection	>65	15 (12-18)	15 (11-17)	15 (11-17)	18 (15-19)	17 (15-19)	17 (15-19)	
blocking	high risk adults	14 (10-17)	14 (11-18)	14 (11-17)	17 (15-20)	17 (15-19)	17 (15-19)	
1 dose	>65 + high risk	15 (11-17)	14 (10-17)	14 (10-17)	17 (14-19)	17 (15-19)	17 (15-19)	
	10 phase	14 (10-17)	13.5 (10-17)	13 (10-16)	17 (15-19)	17 (15-19)	17 (14-19)	
	No priorities	17 (14-19)	16 (14-19)	17 (14-19)	18 (16-20)	18 (16-20)	18 (16-20)	
Symptom	>65	17 (13-19)	16 (12-19)	16 (12-19)	18 (15-20)	17 (15-19)	17 (15-19)	
blocking	high risk adults	17 (12-19)	15 (12-19)	15 (11-18)	18 (15-20)	17 (15-20)	17 (15-19)	
1 dose	>65 + high risk	16 (12-20)	15 (12-19)	14 (11-17)	18 (16-20)	17 (15-19)	17 (15-19)	
	10 phase	16 (12-20)	14 (11-19)	13 (10-17)	17 (15-19)	17 (15-19)	17 (14-19)	
	No priorities	15 (13-18)	15 (13-18)	15 (13-18)	18 (15-20)	18 (15-20)	18 (16-19)	
	>65	15 (12-18)	15 (12-18)	15 (11-18)	18 (15-19)	17 (15-19)	17 (14-19)	
Hybrid 1 dose	high risk adults	15 (11-18)	15 (11-18)	14 (10-17)	17 (15-19)	17 (15-19)	17 (14-19)	
1 4050	>65 + high risk	15 (11-18)	14 (10-18)	14 (10-17)	17 (15-19)	17 (15-19)	17 (15-19)	
	10 phase	14 (11-17)	14 (9-17)	13 (9-16)	17 (15-19)	17 (15-19)	17 (14-19)	

Table A1.2. Peak week of COVID-19 deaths after November 8, 2020. Values are medians and 95% confidence intervals based on 200 pairs of stochastic simulations.

Hybrid scenarios: Infection-blocking and symptom-blocking vaccine

Our model assumes the vaccine is either infection blocking or symptom blocking, while the reality may be somewhere in between. Therefore, we projected the COVID-19 mortality under a

hybrid scenario where two doses of the vaccine are 67% efficacious against all infections and 82% efficacious against developing symptoms, with additional parameters given in Table A2.4.



Figure A1. Projected COVID-19 mortality in the Austin-Round Rock MSA from November 8, 2020 to September 17, 2021 under various vaccine rollout scenarios. A) COVID-19 deaths averted after January 15, 2021 for a hybrid type of vaccination protection under combinations of: vaccine uptake, either 50% or 90% (x-axis); rollout dates, either January 15 (circles) or February 15 (triangles); and risk prioritization, either no priority (gray), prioritize all adults over 65y (light blue), adults with high-risk comorbidities (medium blue), or the combination of the two (dark blue), or a ten-phase risk-ordered strategy that sequentially vaccinates >65y high risk, 50-64y high risk, >65y low risk, 18-49y high risk, 50-64y low risk, 18-49y low risk, 0-4y high risk, 5-17y high risk, 0-4y low risk, 5-17y low risk. Points and whiskers indicate the median and 95% CI across 200 paired stochastic simulations. B) Weekly incident COVID-19 deaths per 100,000 assuming intermediate (70%) uptake (1) without vaccine (black) or under a ten-phase risk-based rollout of a 95% efficacious infection-blocking, starting either January 15 (orange) or February 15 (purple). The brown line assumes that only first doses are administered starting January 15. Solid lines and shading indicate the median and 95% CI across 200 stochastic simulations, respectively.

Section 2. Stochastic Compartmental Model of COVID-19 Transmission in the Austin-Round Rock Metropolitan Area

The model structure is diagrammed in Figure A2 and described in the equations below. For each vaccine, age and risk group, we build a separate set of compartments to model the transitions between the states: susceptible (*S*), exposed (*E*), pre-symptomatic infectious (I^P), symptomatic infectious (I^Y), asymptomatic infectious (I^A), symptomatic infectious that are hospitalized (I^H), recovered (*R*), and deceased (*D*). The symbols *S*, *E*, I^P , I^Y , I^A , I^H , *R*, and *D* denote the number of people in that state in the given vaccine/age/risk group and the total size of the vaccine/age/risk group is $N = S + E + I^P + I^Y + I^A + I^H + R + D$.

The model for individuals in vaccine group *v*, age group *a*, and risk group *r* is given by:

$$\begin{split} \frac{dS_{v,a,r}}{dt} &= -\sum_{u \in V} \sum_{i \in A} \sum_{j \in K} S_{v,a,r} \kappa_{v,a,r} \beta_0 \varphi_{a,i} \left(\omega_u^P I_{u,ij}^P + \omega_u^A I_{u,ij}^A + \omega_u^Y I_{u,ij}^Y \right) / N_i \\ \frac{dE_{v,a,r}}{dt} &= \sum_{u \in V} \sum_{i \in A} \sum_{j \in K} S_{v,a,r} \kappa_{v,a,r} \beta_0 \varphi_{a,i} \left(\omega_u^P I_{u,ij}^P + \omega_u^A I_{u,ij}^A + \omega_u^Y I_{u,ij}^Y \right) / N_i - \sigma E_{v,a,r} \\ \frac{dI_{v,a,r}^A}{dt} &= (1 - \lambda_{v,a,r} \tau) \sigma E_{v,a,r} - \gamma^A I_{v,a,r}^A \\ \frac{dI_{v,a,r}^P}{dt} &= \lambda_{v,a,r} \tau \sigma E_{v,a,r} - \rho I_{v,a,r}^P \\ \frac{dI_{v,a,r}^P}{dt} &= \pi \eta I_{v,a,r}^Y - (1 - \pi) \gamma^Y I_{v,a,r}^Y - \pi \eta I_{v,a,r}^Y \\ \frac{dR_{v,a,r}}{dt} &= \gamma^A I_{v,a,r}^A + (1 - \pi) \gamma^Y I_{v,a,r}^Y + (1 - v) \gamma^H I_{v,a,r}^H \\ \frac{dD_{v,a,r}}{dt} &= v \mu I_{v,a,r}^H \end{split}$$

where *V*, *A* and *K* are all possible vaccine, age and risk groups, ω^A , ω^Y , ω^P are relative infectiousness of the I^A , I^Y , I^P compartments, respectively, β_0 is baseline transmission rate, $\phi_{a,i}$ is the mixing rate between age group *a*, $i \in A$, γ^A, γ^Y , γ^H are the recovery rates for the I^A , I^Y , I^H compartments, respectively, σ is the exposed rate, τ is the symptomatic ratio, ρ is the rate from pre-symptomatic to symptomatic, π is the proportion of symptomatic individuals requiring hospitalization, η is rate at which hospitalized cases enter the hospital following symptom onset, v is mortality rate for hospitalized cases, and μ is rate at which terminal patients die.

The transition between each vaccine group v, is given by

$$\frac{dX_{U,a,r}}{dt} = -\alpha_{a,r}^{i}X_{U,a,r}$$
$$\frac{dX_{W^{i},a,r}}{dt} = \alpha_{a,r}^{i}X_{U,a,r} - \delta^{i}X_{W^{i},a,r}$$
$$\frac{dX_{V^{i},a,r}}{dt} = \delta^{i}X_{W^{i},a,r} - \alpha_{a,r}^{ii}\delta X_{V^{i},a,r}$$
$$\frac{dX_{W^{ii},a,r}}{dt} = \alpha_{a,r}^{ii}\delta X_{V^{i},a,r} - \delta^{ii}X_{W^{ii},a,r}$$
$$\frac{dX_{V^{ii},a,r}}{dt} = \delta^{ii}X_{W^{ii},a,r}$$

where $X \in \{S, E, I^A, I^P, I^Y, I^H, R, D\}$, and $v \in \{U, W^i, V^i, W^{ii}, V^{ii}\}$, α^i is vaccination rate, δ^i is the rate that individuals that receive the first injection gain partial immunity, α^{ii} is second injection adherence rate, δ is the delay in second dose injection, δ^{ii} is the rate that individuals that receive the second injection gain immunity.

We model stochastic transitions between compartments using the τ -leap method (2,3) with key parameters given in Table S1. Assuming that the events at each time-step are independent and do not impact the underlying transition rates, the numbers of each type of event should follow Poisson distributions with means equal to the rate parameters. We thus simulate the model according to the following equations:

$$S_{\nu,a,r}(t+1) - S_{\nu,a,r}(t) = -P_1$$

$$E_{\nu,a,r}(t+1) - E_{\nu,a,r}(t) = P_1 - P_2$$

$$I_{\nu,a,r}^A(t+1) - I_{\nu,a,r}^A(t) = (1 - \lambda_{\nu,a,r}\tau)P_2 - P_3$$

$$I_{\nu,a,r}^P(t+1) - I_{\nu,a,r}^P(t) = \lambda_{\nu,a,r}\tau P_2 - P_4$$

$$I_{\nu,a,r}^Y(t+1) - I_{\nu,a,r}^Y(t) = P_4 - P_5 - P_6$$

$$\begin{split} I_{v,a,r}^{H}(t+1) - I_{v,a,r}^{H}(t) &= P_{6} - P_{7} - P_{8} \\ D_{v,a,r}(t+1) - D_{v,a,r}(t) &= P_{7} \\ R_{v,a,r}(t+1) - R_{v,a,r}(t) &= P_{3} + P_{5} + P_{8} \\ X_{U,a,r}(t+1) - X_{U,a,r}(t) &= -\alpha_{a,r}^{i}(t) X_{U,a,r}(t) \\ X_{W^{i},a,r}(t+1) - X_{W^{i},a,r}(t) &= \alpha_{a,r}^{i}(t) X_{U,a,r}(t) - P_{9} \\ X_{V^{i},a,r}(t+1) - X_{W^{i},a,r}(t) &= P_{9} - P_{10} \\ X_{W^{ii},a,r}(t+1) - X_{W^{ii},a,r}(t) &= P_{10} - P_{11} \\ X_{V^{ii},a,r}(t+1) - X_{V^{ii},a,r}(t) &= P_{11} \end{split}$$

with

$$\begin{split} P_{1} &\sim Pois\left(S_{\nu,a,r}\left(t\right)F_{\nu,a,r}\left(t\right)\right) \\ P_{2} &\sim Pois\left(\sigma E_{\nu,a,r}\left(t\right)\right) \\ P_{3} &\sim Pois\left(\gamma^{A}I_{\nu,a,r}^{A}\left(t\right)\right) \\ P_{4} &\sim Pois\left(\rho I_{\nu,a,r}^{P}\left(t\right)\right) \\ P_{5} &\sim Pois\left(\left(1-\pi\right)\gamma^{Y}I_{\nu,a,r}^{Y}\left(t\right)\right) \\ P_{6} &\sim Pois\left(\pi\eta I_{\nu,a,r}^{Y}\left(t\right)\right) \\ P_{7} &\sim Pois\left(\nu\mu I_{\nu,a,r}^{H}\left(t\right)\right) \\ P_{8} &\sim Pois\left(\left(1-\nu\right)\gamma^{H}I_{\nu,a,r}^{H}\left(t\right)\right) \\ P_{9} &\sim Pois\left(\delta^{i}X_{W^{i},a,r}\left(t\right)\right) \\ P_{10} &\sim Pois\left(\alpha^{ii}\delta X_{V^{i},a,r}\left(t\right)\right) \end{split}$$

$$P_{11} \sim Pois\left(\delta^{ii}X_{W^{ii},a,r}\left(t\right)\right)$$

and where $F_{v,a,r}$ denotes the force of infection for individuals in vaccine group *v*, age group *a*, and risk group *r* and is given by:



$$F_{v,a,r}(t) = \sum_{u \in V} \sum_{i \in A} \sum_{j \in K} \kappa_{v,a,r} \beta_0 \varphi_{a,i} \left(\omega_u^P I_{u,i,j}^P + \omega_u^A I_{u,i,j}^A + \omega_u^Y I_{u,i,j}^Y \right) / N_i$$

Figure A2. Compartmental model of COVID-19 transmission in a US city. Each subgroup (defined by age and risk) is modeled with a separate set of compartments. Upon infection, susceptible individuals (S) progress to exposed (E) and then to either pre-symptomatic infectious (I^{P}) or asymptomatic infectious (I^{A}). All asymptomatic cases eventually progress to a recovered class where they remain protected from future infection (R); pre-symptomatic cases progress to symptomatic (I^{Y}) then are either hospitalized (I^{H}) or recover. Mortality (D) varies by age group and risk group and is assumed to be preceded by hospitalization. For each compartment, individuals may have 5 vaccination status: unvaccinated (U), newly vaccinated with the first dose (W^{i}), vaccinated with the first dose (V^{i}), newly vaccinated with the second dose (W^{ii}), and vaccinated with the second dose (V^{ii}).

Model Parameters

Variable	Settings
Initial day of simulation	11/8/2020
Initial infection number in locations	Number of occupancies in each compartment in Table A2.9 (4)
Age-specific and day-specific contact rates ^a	Home, work, other and school matrices provided in Tables A2.5-A2.8 Normal weekday = home + work + other + school Normal weekday = home + other Normal weekday holiday = home + other Normal weekday during summer or winter break = home + work + other

Table A2.1. Initial conditions and contact rates

^a We assume the age-specific contact rates given in ref. (5), which takes the contact numbers estimated through diary-based POLYMOD study in Europe (6) and extrapolates to the United States. The values in Tables A2.5-A2.8 are the assumed daily contacts between each pair of age groups at home, school, work, and all other places, respectively. These contact matrices are used to adjust the transmission rate between age groups. The accuracy of the contact matrices is limited by (i) possible biases with the original diary-based study (6), (ii) assumptions made when projecting the original study to the US (5), and (iii) impacts of COVID-19 policies and perceptions on daily contact patterns.

Table A2.2. Model parameters. Values given as five-element vectors are age-stratified with values corresponding to 0-4, 5-17, 18-49, 50-64, 65+ year age groups, respectively.

Parameters	Best guess values	Source
R _e	1.2	(4)
β : baseline transmission rate	0.0183	Derived from next generation matrix based on R_e (7)
γ^A : recovery rate on asymptomatic compartment	0.1587	(8)
γ^{Y} : recovery rate on symptomatic non-treated compartment	0.25	(8)
τ : symptomatic proportion (%)	57	(9)
σ : exposed rate	0.3448	(10)
<i>P</i> : proportion of pre-symptomatic (%)	44	(8)
ω^P : relative infectiousness of infectious individuals in compartment P	$\omega^{P} = \frac{\left(\frac{YHR}{\eta} + \frac{1-YHR}{\gamma^{Y}}\right)\omega^{Y}\rho^{P}}{1-P}$	
ω^{A} : relative infectiousness of infectious individuals in compartment I ^A	0.67	(8)
ρ: symptom onset rate	0.43478	2.3 days average from pre-symptomatic to symptomatic
<i>IFR</i> : infected fatality ratio, age specific (%)	Overall: 0.0016, 0.00495, 0.08428, 1.00011, 3.37149] Low risk: [0.00137, 0.00386, 0.06334, 0.60254, 1.73687]	Age adjusted from Verity et al. (11)

	High risk: [0.00412, 0.01157, 0.19001, 1.80762, 5.2106]	
<i>YFR</i> : symptomatic fatality ratio, age specific (%)	Overall: [0.00281, 0.00868, 0.14785, 1.75458, 5.9149] Low risk: [0.00241, 0.00677, 0.11112, 1.05709, 3.04713] High risk: [0.00722, 0.0203, 0.33336, 3.17127, 9.1414]	$YFR = \frac{IFR}{\tau}$
<i>h</i> : high-risk proportion, age specific (%)	[8.2825, 14.1121, 16.5298, 32.9912, 47.0568]	Estimated using 2015-2016 Behavioral Risk Factor Surveillance System (BRFSS) data with multilevel regression and poststratification using CDC's list of conditions that may increase the risk of serious complications from influenza (12–14)
<i>rr</i> : relative risk for high risk people compared to low risk in their age group	3	(15)
School calendars	Austin Independent School District calendar (2019-2020, 2020-2021)	(16)

 Table A2.3. Hospitalization parameters

Parameters	Value	Source
γ^H : recovery rate in hospitalized compartment	0.0935	Austin admissions and discharge data (Avg=10.96. 95% CI = 9.37 to 12.76) (17,18)
<i>YHR</i> : symptomatic case hospitalization rate (%)	Overall: [0.07018, 0.07018, 4.73526, 16.32983, 25.54183] Low risk: [0.0602, 0.05473, 3.55875, 9.83829, 13.15819] High risk: [0.18061, 0.16419, 10.67625, 29.51487, 39.47457]	Age adjusted from Verity et al. (11)
π : rate of symptomatic individuals go to hospital, age-specific	$\pi = \frac{\gamma^{Y} \cdot Y HR}{\eta + (\gamma^{Y} - \eta)Y HR}$	
η : rate from symptom onset to hospitalized	0.1695	5.9 day average from symptom onset to hospital admission Tindale et al. (19)
μ : rate from hospitalized to death	0.1235	Austin admissions and discharge data (Avg=7.8, 95% CI = 5.21 to 10.09) (17,18)
<i>HFR</i> : hospitalized fatality ratio, age specific (%)	[4, 12.365, 3.122, 10.745, 23.158]	$HFR = \frac{IFR}{YHR\tau}$
v : death rate on hospitalized individuals, age specific	$\nu = \frac{\gamma^H HFR}{\mu + (\gamma^H - \mu)HFR}$	

Table A2.4. Vaccine parameters

Parameters	Value	Source
Vaccine efficacy - full course vaccination, infection-blocking or symptom blocking	After 1st dose and before 2nd dose: ~ <i>Triangular</i> (0.295, 0.524, 0.684) After 2nd dose: ~ <i>Triangular</i> (0.898, 0.948, 0.976)	(20)
Vaccine efficacy - single dose only, infection-blocking or symptom blocking	After 1st dose (longterm): ~ <i>Triangular</i> (0.756, 0.82, 0.869)	(20)
Vaccine efficacy - full course vaccination, hybrid	After 1st dose and before 2nd dose on infection: 0.524 After 1st dose and before 2nd dose on symptomatic ratio: 0 After 2nd dose on infection: 0.67 After 2nd dose on symptomatic ratio: ~ <i>Triangular</i> (0.691, 0.82, 0.927)	(20,21)
Vaccine efficacy - single dose only, hybrid	After 1st dose (longterm) on infection: 0.67 After 1st dose (longterm) on symptomatic ratio: ~ <i>Triangular</i> (0.261, 0.455, 0.603)	(20,21)
Vaccine adherence rate	0.5, 0.7, 0.9	(1,22), 0.9 is hypothetical
2nd dose return rate	0.8	Assumption
Vaccine rollout schedule	10M nationwide per week and adjusted by Austin MSA population	(23) and discussion with CDC
Days between doses	28	(24)
Days to gain immunity	14 and 14 after the 1st and 2nd dose	Based on discussion with virologist and immunologist

	0-4y	5-17y	18-49y	50-64y	65y+
0-4y	0.5	0.9	2.0	0.1	0.0
5-17y	0.2	1.7	1.9	0.2	0.0
18-49y	0.2	0.9	1.7	0.2	0.0
50-64y	0.2	0.7	1.2	1.0	0.1
65y+	0.1	0.7	1.0	0.3	0.6

Table A2.5. Home contact matrix (daily number contacts by age group at home)

Table A2.6. School contact matrix (daily number contacts by age group at school)

	0-4y	5-17y	18-49y	50-64y	65y+
0-4y	1.0	0.5	0.4	0.1	0.0
5-17y	0.2	3.7	0.9	0.1	0.0
18-49y	0.0	0.7	0.8	0.0	0.0
50-64y	0.1	0.8	0.5	0.1	0.0
65y+	0.0	0.0	0.1	0.0	0.0

 Table A2.7. Work contact matrix (daily number contacts by age group at work)

	0-4y	5-17y	18-49y	50-64y	65y+
0-4y	0.0	0.0	0.0	0.0	0.0
5-17y	0.0	0.1	0.4	0.0	0.0
18-49y	0.0	0.2	4.5	0.8	0.0
50-64y	0.0	0.1	2.8	0.9	0.0
65y+	0.0	0.0	0.1	0.0	0.0

	0-4y	5-17y	18-49y	50-64y	65y+
0-4y	0.7	0.7	1.8	0.6	0.3
5-17y	0.2	2.6	2.1	0.4	0.2
18-49y	0.1	0.7	3.3	0.6	0.2
50-64y	0.1	0.3	2.2	1.1	0.4
65y+	0.0	0.2	1.3	0.8	0.6

Table A2.8. Others contact matrix (daily number contacts by age group at other locations)

Table A2.9. Initial conditions of model compartments

Age	Risk	S	Е	IA	IP	IY	IH	R	D
0-4 yr	High	8809	7	5	3	5	0	524	0
0-4 yr	Low	121035	95	87	42	73	0	7190	0
5-17 yr	High	33884	40	39	21	33	0	3418	0
	Low	296425	372	343	169	279	0	29580	1
18-49 yr	High	142443	165	143	70	140	35	13158	26
	Low	834952	949	884	442	746	21	77836	16
50.64 yr	High	100333	102	84	44	87	42	7262	255
50-64 yr	Low	231158	219	201	97	171	9	17370	57
65+ yr	High	100101	45	40	21	43	20	3261	236
	Low	127788	60	55	26	51	2	4485	31

Section 3. Sensitivity Analyses

Sensitivity analysis with respect to the effective reproduction number (R_e) of the virus in November 8, 2021

Our base scenarios assume an effective reproductive number (R_e) of 1.2 (4). Here, we provide projections based on a higher reproductive number $R_e=1.5$. Under this higher transmission scenario, a vaccine campaign starting on February 15, 2021 starts close to the pandemic peak (in terms of COVID-19 deaths) and thus barely impacts the overall mortality.



Figure A3.1. Projected COVID-19 mortality in the Austin-Round Rock MSA from November 8, 2020 to September 17, 2021 under various vaccine rollout scenarios. A) COVID-19 deaths averted after January 15, 2021 under combinations of: vaccine uptake, either 50% (left) or 90% (right); type of protection, either infection or symptom blocking (x-axis); rollout dates, either January 15 (circles) or February 15 (triangles); and risk prioritization, either no priority (gray), prioritize all adults over 65y (light blue), adults with high-risk comorbidities (medium blue), or the combination of the two (dark blue), or a ten-phase risk-ordered strategy that sequentially vaccinates >65y high risk, 50-64y high risk, >65y low risk, 18-49y high risk, 50-64y low risk, 18-49y low risk, 0-4y high risk, 5-17y high risk, 0-4y low risk, 5-17y low risk. Points and whiskers indicate the median and 95% CI across 200 paired stochastic simulations. B) Weekly incident COVID-19 deaths per 100,000 assuming intermediate (70%) uptake (1) without vaccine (black) or under a ten-phase risk-based rollout of a 95% efficacious infection-blocking, starting either January 15 (orange) or February 15 (purple). The brown line assumes that only first doses are administered starting January 15. Solid lines and shading indicate the median and 95% CI across 200 stochastic simulations, respectively.

Sensitivity analysis with respect to prior immunity as of November 8, 2020

We initially assume 7.6% of the individuals in the population have obtained immunity due to prior infection (Table A2.9) (4). Here, we double (15.2%) the proportion immune.





Figure A3.2. Projected COVID-19 mortality in the Austin-Round Rock MSA from November 8, 2020 to September 17, 2021 under various vaccine rollout scenarios. A) COVID-19 deaths averted after January 15, 2021 under combinations of: vaccine uptake, either 50% (left) or 90% (right); type of protection, either infection or symptom blocking (x-axis); rollout dates, either January 15 (circles) or February 15 (triangles); and risk prioritization, either no priority (gray), prioritize all adults over 65y (light blue), adults with high-risk comorbidities (medium blue), or the combination of the two (dark blue), or a ten-phase risk-ordered strategy that sequentially vaccinates >65y high risk, 50-64y high risk, >65y low risk, 18-49y high risk, 50-64y low risk, 18-49y low risk, 0-4y high risk, 5-17y high risk, 0-4y low risk, 5-17y low risk. Points and whiskers indicate the median and 95% CI across 200 paired stochastic simulations. B) Weekly incident COVID-19 deaths per 100,000 assuming intermediate (70%) uptake (1) without vaccine (black) or under a ten-phase risk-based rollout of a 95% efficacious infection-blocking, starting either January 15 (orange) or February 15 (purple). The brown line assumes that only first doses are administered starting January 15. Solid lines and shading indicate the median and 95% CI across 200 stochastic simulations, respectively.

Section 4. Estimation of age-stratified proportion of population at high-risk for COVID-10 complications

We estimate age-specific proportions of the population at high risk of complications from COVID-19 based on data for Austin, TX and Round-Rock, TX from the CDC's 500 cities project (Figure A5) (25). We assume that high risk conditions for COVID-19 are the same as those specified for influenza by the CDC (12). The CDC's 500 cities project provides city-specific estimates of prevalence for several of these conditions among adults (26). The estimates were obtained from the 2015-2016 Behavioral Risk Factor Surveillance System (BRFSS) data using a small-area estimation methodology called multi-level regression and poststratification (14,27). It links geocoded health surveys to high spatial resolution population demographic and socioeconomic data (14).

Estimating high-risk proportions for adults

To estimate the proportion of adults at high risk for complications, we use the CDC's 500 cities data, as well as data on the prevalence of HIV/AIDS, obesity and pregnancy among adults (Table A7). The CDC 500 cities dataset includes the prevalence of each condition on its own, rather than the prevalence of multiple conditions (e.g., dyads or triads). Thus, we use separate co-morbidity estimates to determine overlap. Reference about chronic conditions (28) gives US estimates for the proportion of the adult population with 0, 1 or 2+ chronic conditions, per age group. Using this and the 500 cities data we can estimate the proportion of the population pHR in each age group in each city with at least one chronic condition listed in the CDC 500 cities data (Table A7) putting them at high-risk for flu complications.

<u>HIV</u>: We use the data from table 20a in CDC HIV surveillance report (29) to estimate the population in each risk group living with HIV in the US (last column, 2015 data). Assuming independence between HIV and other chronic conditions, we increase the proportion of the population at high-risk for influenza to account for individuals with HIV but no other underlying conditions.

<u>Morbid obesity</u>: A BMI over 40kg/m² indicates morbid obesity, and is considered high risk for influenza. The 500 Cities Project reports the prevalence of obese people in each city with BMI over 30kg/m² (not necessarily morbid obesity). We use the data from table 1 in Sturm and Hattori (30) to estimate the proportion of people with BMI>30 that actually have BMI>40

(across the US); we then apply this to the 500 Cities obesity data to estimate the proportion of people who are morbidly obese in each city. Table 1 of Morgan et al. (31) suggests that 51.2% of morbidly obese adults have at least one other high risk chronic condition, and update our high-risk population estimates accordingly to account for overlap.

<u>Pregnancy</u>: We separately estimate the number of pregnant women in each age group and each city, following the methodology in CDC reproductive health report (32). We assume independence between any of the high-risk factors and pregnancy, and further assume that half the population are women.

Estimating high-risk proportions for children

Since the 500 Cities Project only reports data for adults 18 years and older, we take a different approach to estimating the proportion of children at high risk for severe influenza. The two most prevalent risk factors for children are asthma and obesity; we also account for childhood diabetes, HIV and cancer.

From Miller et al. (33), we obtain national estimates of chronic conditions in children. For asthma, we assume that variation among cities will be similar for children and adults. Thus, we use the relative prevalences of asthma in adults to scale our estimates for children in each city. The prevalence of HIV and cancer in children are taken from CDC HIV surveillance report (29) and cancer research report (34), respectively.

We first estimate the proportion of children having either asthma, diabetes, cancer or HIV (assuming no overlap in these conditions). We estimate city-level morbid obesity in children using the estimated morbid obesity in adults multiplied by a national constant ratio for each age group estimated from Hales et al. (35), this ratio represents the prevalence in morbid obesity in children given the one observed in adults. From Morgan et al. (31), we estimate that 25% of morbidly obese children have another high-risk condition and adjust our final estimates accordingly.

Resulting estimates

We compare our estimates for the Austin-Round Rock Metropolitan Area to published national-level estimates (36) of the proportion of each age group with underlying high risk conditions (Table A8). The biggest difference is observed in older adults, with Austin having a lower proportion at risk for complications for COVID-19 than the national average; for 25-39 year olds the high risk proportion is slightly higher than the national average.



Figure A4. Demographic and risk composition of the Austin-Round Rock MSA. Bars indicate age-specific population sizes, separated by low risk, high risk, and pregnant. High risk is defined as individuals with cancer, chronic kidney disease, COPD, heart disease, stroke, asthma, diabetes, HIV/AIDS, and morbid obesity, as estimated from the CDC 500 Cities Project (25), reported HIV prevalence (29) and reported morbid obesity prevalence (30,31), corrected for multiple conditions. The population of pregnant women is derived using the CDC's method combining fertility, abortion and fetal loss rates (37–39).

Condition	Data source
Cancer (except skin), chronic kidney disease, COPD, coronary heart disease, stroke, asthma, diabetes	CDC 500 cities (25)
HIV/AIDS	CDC HIV Surveillance report (26)
Obesity	CDC 500 cities (25), Sturm and Hattori (30), Morgan et al. (31)
Pregnancy	National Vital Statistics Reports (37) and abortion data (38)

Table A4.1 High-risk conditions for influenza and data sources for preval	lence estimation
---	------------------

Age Group	National estimates (35)	Austin (excluding pregnancy)	Pregnant women (proportion of age group)
0 to 6 months	NA	6.8	-
6 months to 4 years	6.8	7.4	-
5 to 9 years	11.7	11.6	-
10 to 14 years	11.7	13.0	-
15 to 19 years	11.8	13.3	1.7
20 to 24 years	12.4	10.3	5.1
25 to 34 years	15.7	13.5	7.8
35 to 39 years	15.7	17.0	5.1
40 to 44 years	15.7	17.4	1.2
45 to 49 years	15.7	17.7	-
50 to 54 years	30.6	29.6	-
55 to 60 years	30.6	29.5	-
60 to 64 years	30.6	29.3	-
65 to 69 years	47.0	42.2	-
70 to 74 years	47.0	42.2	-
75 years and older	47.0	42.2	-

 Table A4.2. Comparison between published national estimates and Austin-Round Rock MSA estimates of the percent of the population at high-risk of influenza/COVID-19 complications.

References

- U.S. Public Now Divided Over Whether To Get COVID-19 Vaccine [Internet]. 2020 [cited 2020 Dec 14]. Available from: https://www.pewresearch.org/science/2020/09/17/u-s-public-now-divided-over-whether-to-g et-covid-19-vaccine/
- 2. Keeling MJ, Rohani P. Modeling Infectious Diseases in Humans and Animals. Princeton University Press; 2011. 408 p.
- 3. Gillespie DT. Approximate accelerated stochastic simulation of chemically reacting systems. J Chem Phys. 2001 Jul 22;115(4):1716–33.
- 4. Austin Dashboard [Internet]. [cited 2020 Dec 8]. Available from: https://covid-19.tacc.utexas.edu/dashboards/austin/
- 5. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Comput Biol. 2017 Sep;13(9):e1005697.
- Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008 Mar 25;5(3):e74.
- 7. Diekmann O, Heesterbeek JAP, Roberts MG. The construction of next-generation matrices for compartmental epidemic models. J R Soc Interface. 2010 Jun 6;7(47):873–85.
- 8. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med [Internet]. 2020 Apr 15; Available from: http://dx.doi.org/10.1038/s41591-020-0869-5
- Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population. N Engl J Med [Internet]. 2020 Apr 14; Available from: http://dx.doi.org/10.1056/NEJMoa2006100
- Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis [Internet]. 2020 Apr 2; Available from: http://dx.doi.org/10.1016/S1473-3099(20)30230-9
- 11. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of COVID-19 disease [Internet]. Epidemiology. medRxiv; 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.03.09.20033357v1.abstract
- 12. CDC. People at High Risk of Flu [Internet]. Centers for Disease Control and Prevention. 2019 [cited 2020 Mar 26]. Available from: https://www.cdc.gov/flu/highrisk/index.htm
- 13. CDC BRFSS [Internet]. 2019 [cited 2020 Mar 26]. Available from: https://www.cdc.gov/brfss/index.html
- 14. Zhang X, Holt JB, Lu H, Wheaton AG, Ford ES, Greenlund KJ, et al. Multilevel regression and poststratification for small-area estimation of population health outcomes: a case study

of chronic obstructive pulmonary disease prevalence using the behavioral risk factor surveillance system. Am J Epidemiol. 2014 Apr 15;179(8):1025–33.

- 15. CDC. COVID-19 and Your Health [Internet]. 2020 [cited 2021 Jan 15]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html
- 16. Calendar of Events [Internet]. Austin ISD. [cited 2020 Mar 26]. Available from: https://www.austinisd.org/calendar
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052–9.
- 18. Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. BMJ. 2020 May 22;369:m1923.
- 19. Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M, et al. Transmission interval estimates suggest pre-symptomatic spread of COVID-19 [Internet]. Epidemiology. medRxiv; 2020. Available from: http://dx.doi.org/10.1101/2020.03.03.20029983
- 20. Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document- FDA. Available from: https://www.fda.gov/media/144245/download
- 21. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document Addendum- Sponsor. Available from: https://www.fda.gov/media/144453/download
- 22. Neergaard L. AP-NORC poll: Half of Americans would get a COVID-19 vaccine [Internet]. Associated Press. 2020 [cited 2021 Jan 14]. Available from: https://apnews.com/article/dacdc8bc428dd4df6511bfa259cfec44
- 23. Operation Warp Speed Leaders Say 20 Million COVID-19 Vaccines May Be Available This Month [Internet]. [cited 2021 Jan 13]. Available from: https://www.defense.gov/Explore/News/Article/Article/2432663/operation-warp-speed-leade rs-say-20-million-covid-19-vaccines-may-be-available/
- 24. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document - FDA. Available from: https://www.fda.gov/media/144434/download
- 25. 500 Cities Project: Local data for better health | Home page | CDC [Internet]. 2019 [cited 2020 Jun 22]. Available from: https://www.cdc.gov/500cities/index.htm
- 26. Health Outcomes | 500 Cities [Internet]. 2019 [cited 2020 Jun 22]. Available from: https://www.cdc.gov/500cities/definitions/health-outcomes.htm
- 27. CDC BRFSS [Internet]. 2019 [cited 2020 Jun 22]. Available from: https://www.cdc.gov/brfss/index.html
- 28. Part One: Who Lives with Chronic Conditions [Internet]. Pew Research Center: Internet,

Science & Tech. 2013 [cited 2020 Jun 22]. Available from: https://www.pewresearch.org/internet/2013/11/26/part-one-who-lives-with-chronic-condition s/

- 29. for Disease Control C, Prevention, Others. HIV surveillance report. 2016; 28. URL: http://www.cdc.gov/hiv/library/reports/hiv-surveil-lance.html Published November. 2017;
- 30. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes. 2013 Jun 1;37(6):889–91.
- Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, et al. Morbid Obesity as a Risk Factor for Hospitalization and Death Due to 2009 Pandemic Influenza A(H1N1) Disease [Internet]. Vol. 5, PLoS ONE. 2010. p. e9694. Available from: http://dx.doi.org/10.1371/journal.pone.0009694
- 32. Estimating the Number of Pregnant Women in a Geographic Area from CDC Division of Reproductive Health. Available from: https://www.cdc.gov/reproductivehealth/emergency/pdfs/PregnacyEstimatoBrochure508.pdf
- 33. Miller GF, Coffield E, Leroy Z, Wallin R. Prevalence and Costs of Five Chronic Conditions in Children. J Sch Nurs. 2016 Oct;32(5):357–64.
- 34. American Cancer Society. [cited 2020 Jun 22]; Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts -figures-2014.html
- 35. Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016. JAMA. 2018 Apr 24;319(16):1723–5.
- 36. Zimmerman RK, Lauderdale DS, Tan SM, Wagener DK. Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine. 2010 Sep 7;28(39):6470–7.
- 37. Martin JA. MPH, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: final data for 2017 [internet]. National Vital Statistics Reports CDC. 2018;
- 38. Jatlaoui TC, Boutot ME, Mandel MG, Whiteman MK, Ti A, Petersen E, et al. Abortion Surveillance - United States, 2015. MMWR Surveill Summ. 2018 Nov 23;67(13):1–45.
- Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Natl Vital Stat Rep. 2012;60(7):1–21.